Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Medicine

Cancer Oncology

Pathology

Internal Medicine

Gastroenterology

Show all topics

DOI

10.1016/s0140-6736(17)32247-x

Other Formats

PDF